Theradiag Announces Its 2021 Financial Calendar
15 Dicembre 2020 - 5:45PM
Business Wire
Regulatory News:
THERADIAG (Paris:ALTER) (ISIN: FR0004197747, Ticker:
ALTER), a company specializing in in vitro diagnostics of
autoimmune diseases and theranostics, today announces its schedule
for the publication of financial information for 2021.
Events
Dates*
2020 Full-Year Annual Revenue
Monday February 1, 2021
2020 Full-Year Results
Monday March 22, 2021
Annual General Meeting
Thursday May 6, 2021
2021 First-Half Revenue
Monday July 19, 2021
2021 First-Half Results
Monday September 20, 2021
(*) Subject to modifications. Press releases will be published
before market opening.
***
About Theradiag
Theradiag is the market leader in biotherapy monitoring.
Capitalizing on its expertise in the diagnostics market, the
Company has been developing, manufacturing and marketing innovative
in vitro diagnostic (IVD) tests for over 30 years.
Theradiag pioneered “theranostics” testing (combining therapy
with diagnosis), which measures the efficacy of biotherapy in the
treatment of chronic inflammatory diseases. Going beyond mere
diagnosis, theranostics aims to help clinicians set up “customized
treatment” for each patient. This method favors the
individualization of treatment, evaluation of its efficacy and the
prevention of drug resistance. In response to this challenge,
Theradiag develops and markets the CE-marked TRACKER® range, a
comprehensive solution of inestimable medical value.
The Company is based in Marne-la-Vallée, near Paris, has
operations in over 70 countries and employs over 60 people. In
2019, the Company posted revenue of €9.6 million. The Theradiag
share is listed on Euronext Growth Paris (ISIN: FR0004197747) and
is eligible for the French PEA-PME personal equity plan.
For more information about Theradiag, please visit our website:
www.theradiag.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201215005735/en/
Theradiag Bertrand de Castelnau CEO/Managing
Director Tel.: +33 (0)1 64 62 10 12
contact@theradiag.com
NewCap Financial Communications &
Investor Relations Louis-Victor Delouvrier Quentin
Massé Tel.: +33 (0)1 44 71 94 94
theradiag@newcap.eu
NewCap Media Relations Nicolas
Mérigeau Tel.: +33 (0)1 44 71 94 98 nmerigeau@newcap.fr
Grafico Azioni Theradiag (EU:ALTER)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Theradiag (EU:ALTER)
Storico
Da Apr 2023 a Apr 2024
